Iruplinalkib

Small moleculeexperimental

Clinical trial activity

9 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
7
Phase 3
1
Phase 4
0

Earliest trial started Sep 14, 2017 (NCT03389815)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2019

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc(N2CCC3(CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1
Mol. weight
569.09 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06697990Phase 2Dec 1, 2024Tianjin Medical University
NCT06436885Early Phase 1 (Phase 1)Feb 28, 2024Henan Medical University
NCT05765877Phase 2Mar 31, 2023Shandong University
NCT05351320Phase 2Apr 30, 2022Shandong University
NCT05801107Phase 2Oct 25, 2021Qilu Pharmaceutical Co., Ltd.
NCT05716126Phase 1Apr 15, 2020Qilu Pharmaceutical Co., Ltd.
NCT04632758Phase 3Jun 1, 2019Qilu Pharmaceutical Co., Ltd.
NCT04641754Phase 2Mar 7, 2019Qilu Pharmaceutical Co., Ltd.
NCT03389815Phase 1/Phase 2 (Phase 2)Sep 14, 2017Capital Medical University, China Medical University, Chinese Academy of Medical Sciences, Qilu Pharmaceutical Co., Ltd.
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Qilu Pharmaceutical Co., Ltd.For profit5532017
Shandong UniversityAcademic/Hospital2212022
Capital Medical UniversityAcademic/Hospital1012017
China Medical UniversityAcademic/Hospital1012017
Chinese Academy of Medical SciencesAcademic/Hospital1012017
Henan Medical UniversityAcademic/Hospital1112024
Tianjin Medical UniversityAcademic/Hospital1112024
7 organizations
Page 1 / 1